nodes	percent_of_prediction	percent_of_DWPC	metapath
Cladribine—SLC22A2—Cisplatin—esophageal cancer	0.113	0.325	CbGbCtD
Cladribine—ABCG2—Carboplatin—esophageal cancer	0.098	0.28	CbGbCtD
Cladribine—ABCG2—Cisplatin—esophageal cancer	0.0837	0.24	CbGbCtD
Cladribine—ABCG2—Methotrexate—esophageal cancer	0.0544	0.156	CbGbCtD
Cladribine—RRM1—larynx—esophageal cancer	0.0163	0.121	CbGeAlD
Cladribine—POLE2—lung—esophageal cancer	0.00647	0.0477	CbGeAlD
Cladribine—RRM2B—bronchus—esophageal cancer	0.00588	0.0434	CbGeAlD
Cladribine—POLE3—bronchus—esophageal cancer	0.00556	0.0411	CbGeAlD
Cladribine—RRM2B—trachea—esophageal cancer	0.00528	0.039	CbGeAlD
Cladribine—POLE3—trachea—esophageal cancer	0.00499	0.0369	CbGeAlD
Cladribine—Floxuridine—TYMP—esophageal cancer	0.00493	0.493	CrCbGaD
Cladribine—PNP—digestive system—esophageal cancer	0.0049	0.0361	CbGeAlD
Cladribine—SLC28A3—trachea—esophageal cancer	0.00467	0.0345	CbGeAlD
Cladribine—POLE2—lymph node—esophageal cancer	0.00442	0.0326	CbGeAlD
Cladribine—POLE3—digestive system—esophageal cancer	0.0043	0.0317	CbGeAlD
Cladribine—PNP—lung—esophageal cancer	0.00409	0.0302	CbGeAlD
Cladribine—SLC28A3—digestive system—esophageal cancer	0.00402	0.0297	CbGeAlD
Cladribine—Trifluridine—TYMP—esophageal cancer	0.00391	0.392	CrCbGaD
Cladribine—POLE—trachea—esophageal cancer	0.00381	0.0281	CbGeAlD
Cladribine—RRM2B—lung—esophageal cancer	0.0038	0.028	CbGeAlD
Cladribine—POLE3—lung—esophageal cancer	0.00359	0.0265	CbGeAlD
Cladribine—RRM2—bronchus—esophageal cancer	0.00349	0.0258	CbGeAlD
Cladribine—SLC28A3—lung—esophageal cancer	0.00336	0.0248	CbGeAlD
Cladribine—POLE—digestive system—esophageal cancer	0.00328	0.0242	CbGeAlD
Cladribine—RRM1—bronchus—esophageal cancer	0.0029	0.0214	CbGeAlD
Cladribine—RRM1—smooth muscle tissue—esophageal cancer	0.00284	0.021	CbGeAlD
Cladribine—POLE—lung—esophageal cancer	0.00274	0.0202	CbGeAlD
Cladribine—RRM2—digestive system—esophageal cancer	0.0027	0.0199	CbGeAlD
Cladribine—RRM2B—lymph node—esophageal cancer	0.0026	0.0192	CbGeAlD
Cladribine—POLE3—lymph node—esophageal cancer	0.00245	0.0181	CbGeAlD
Cladribine—POLA1—lung—esophageal cancer	0.00236	0.0174	CbGeAlD
Cladribine—DCK—bronchus—esophageal cancer	0.00225	0.0166	CbGeAlD
Cladribine—RRM2—lung—esophageal cancer	0.00225	0.0166	CbGeAlD
Cladribine—RRM1—digestive system—esophageal cancer	0.00224	0.0166	CbGeAlD
Cladribine—SLC22A2—digestive system—esophageal cancer	0.0021	0.0155	CbGeAlD
Cladribine—DCK—trachea—esophageal cancer	0.00202	0.0149	CbGeAlD
Cladribine—RRM1—lung—esophageal cancer	0.00187	0.0138	CbGeAlD
Cladribine—POLE—lymph node—esophageal cancer	0.00187	0.0138	CbGeAlD
Cladribine—DCK—digestive system—esophageal cancer	0.00174	0.0129	CbGeAlD
Cladribine—POLA1—lymph node—esophageal cancer	0.00161	0.0119	CbGeAlD
Cladribine—RRM2—lymph node—esophageal cancer	0.00154	0.0114	CbGeAlD
Cladribine—DCK—lung—esophageal cancer	0.00145	0.0107	CbGeAlD
Cladribine—RRM1—lymph node—esophageal cancer	0.00128	0.00946	CbGeAlD
Cladribine—Adenosine monophosphate—PDE4D—esophageal cancer	0.00114	0.115	CrCbGaD
Cladribine—Paralysis—Methotrexate—esophageal cancer	0.00101	0.00427	CcSEcCtD
Cladribine—Renal failure acute—Cisplatin—esophageal cancer	0.00101	0.00425	CcSEcCtD
Cladribine—Blood bilirubin increased—Capecitabine—esophageal cancer	0.001	0.00421	CcSEcCtD
Cladribine—Interstitial lung disease—Methotrexate—esophageal cancer	0.000996	0.00419	CcSEcCtD
Cladribine—DCK—lymph node—esophageal cancer	0.000995	0.00734	CbGeAlD
Cladribine—Bone pain—Capecitabine—esophageal cancer	0.000988	0.00416	CcSEcCtD
Cladribine—Inflammation—Capecitabine—esophageal cancer	0.000976	0.00411	CcSEcCtD
Cladribine—Cerebrovascular accident—Cisplatin—esophageal cancer	0.000952	0.004	CcSEcCtD
Cladribine—Pulmonary embolism—Capecitabine—esophageal cancer	0.000947	0.00399	CcSEcCtD
Cladribine—Injection site reaction—Capecitabine—esophageal cancer	0.000941	0.00396	CcSEcCtD
Cladribine—Herpes zoster—Methotrexate—esophageal cancer	0.000936	0.00394	CcSEcCtD
Cladribine—Depressed level of consciousness—Capecitabine—esophageal cancer	0.000914	0.00385	CcSEcCtD
Cladribine—Fungal infection—Methotrexate—esophageal cancer	0.000913	0.00384	CcSEcCtD
Cladribine—Candida infection—Capecitabine—esophageal cancer	0.000904	0.0038	CcSEcCtD
Cladribine—Petechiae—Methotrexate—esophageal cancer	0.000857	0.00361	CcSEcCtD
Cladribine—Neoplasm—Capecitabine—esophageal cancer	0.000856	0.0036	CcSEcCtD
Cladribine—Ecchymosis—Capecitabine—esophageal cancer	0.000856	0.0036	CcSEcCtD
Cladribine—Sepsis—Capecitabine—esophageal cancer	0.000822	0.00346	CcSEcCtD
Cladribine—ABCG2—lung—esophageal cancer	0.000812	0.00599	CbGeAlD
Cladribine—Extravasation—Methotrexate—esophageal cancer	0.000808	0.0034	CcSEcCtD
Cladribine—Phlebitis—Capecitabine—esophageal cancer	0.000798	0.00336	CcSEcCtD
Cladribine—Sweating increased—Cisplatin—esophageal cancer	0.000785	0.0033	CcSEcCtD
Cladribine—Bone disorder—Methotrexate—esophageal cancer	0.00078	0.00328	CcSEcCtD
Cladribine—Swelling—Capecitabine—esophageal cancer	0.000779	0.00328	CcSEcCtD
Cladribine—Abdominal discomfort—Cisplatin—esophageal cancer	0.000773	0.00325	CcSEcCtD
Cladribine—Vascular purpura—Capecitabine—esophageal cancer	0.000768	0.00323	CcSEcCtD
Cladribine—Pancytopenia—Cisplatin—esophageal cancer	0.000765	0.00322	CcSEcCtD
Cladribine—Hepatic failure—Capecitabine—esophageal cancer	0.000765	0.00322	CcSEcCtD
Cladribine—Haemolytic anaemia—Capecitabine—esophageal cancer	0.000761	0.0032	CcSEcCtD
Cladribine—Hyperuricaemia—Methotrexate—esophageal cancer	0.00076	0.0032	CcSEcCtD
Cladribine—Renal failure acute—Capecitabine—esophageal cancer	0.000744	0.00313	CcSEcCtD
Cladribine—Inflammation—Methotrexate—esophageal cancer	0.000727	0.00306	CcSEcCtD
Cladribine—Atrial fibrillation—Capecitabine—esophageal cancer	0.000725	0.00305	CcSEcCtD
Cladribine—Renal impairment—Capecitabine—esophageal cancer	0.000722	0.00304	CcSEcCtD
Cladribine—Blood uric acid increased—Methotrexate—esophageal cancer	0.000718	0.00302	CcSEcCtD
Cladribine—Purpura—Capecitabine—esophageal cancer	0.000713	0.003	CcSEcCtD
Cladribine—Arthritis—Capecitabine—esophageal cancer	0.000707	0.00298	CcSEcCtD
Cladribine—Renal failure—Cisplatin—esophageal cancer	0.000706	0.00297	CcSEcCtD
Cladribine—Pulmonary embolism—Methotrexate—esophageal cancer	0.000705	0.00297	CcSEcCtD
Cladribine—Cardiac failure—Capecitabine—esophageal cancer	0.000704	0.00296	CcSEcCtD
Cladribine—Lethargy—Capecitabine—esophageal cancer	0.000701	0.00295	CcSEcCtD
Cladribine—Cerebrovascular accident—Capecitabine—esophageal cancer	0.000701	0.00295	CcSEcCtD
Cladribine—Conjunctivitis—Cisplatin—esophageal cancer	0.000698	0.00294	CcSEcCtD
Cladribine—Pain in extremity—Capecitabine—esophageal cancer	0.000687	0.00289	CcSEcCtD
Cladribine—Depressed level of consciousness—Methotrexate—esophageal cancer	0.000681	0.00286	CcSEcCtD
Cladribine—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00068	0.00286	CcSEcCtD
Cladribine—Aplastic anaemia—Methotrexate—esophageal cancer	0.000662	0.00279	CcSEcCtD
Cladribine—Ataxia—Capecitabine—esophageal cancer	0.000646	0.00272	CcSEcCtD
Cladribine—Neoplasm—Methotrexate—esophageal cancer	0.000637	0.00268	CcSEcCtD
Cladribine—Ecchymosis—Methotrexate—esophageal cancer	0.000637	0.00268	CcSEcCtD
Cladribine—Urinary tract disorder—Cisplatin—esophageal cancer	0.000637	0.00268	CcSEcCtD
Cladribine—Connective tissue disorder—Cisplatin—esophageal cancer	0.000634	0.00267	CcSEcCtD
Cladribine—Urethral disorder—Cisplatin—esophageal cancer	0.000632	0.00266	CcSEcCtD
Cladribine—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000619	0.00261	CcSEcCtD
Cladribine—Sepsis—Methotrexate—esophageal cancer	0.000612	0.00257	CcSEcCtD
Cladribine—Muscular weakness—Capecitabine—esophageal cancer	0.000606	0.00255	CcSEcCtD
Cladribine—Eye disorder—Cisplatin—esophageal cancer	0.000603	0.00254	CcSEcCtD
Cladribine—Cardiac disorder—Cisplatin—esophageal cancer	0.000599	0.00252	CcSEcCtD
Cladribine—Immune system disorder—Cisplatin—esophageal cancer	0.000583	0.00245	CcSEcCtD
Cladribine—Mediastinal disorder—Cisplatin—esophageal cancer	0.000581	0.00245	CcSEcCtD
Cladribine—Sweating increased—Capecitabine—esophageal cancer	0.000579	0.00244	CcSEcCtD
Cladribine—Arrhythmia—Cisplatin—esophageal cancer	0.000576	0.00243	CcSEcCtD
Cladribine—Alopecia—Cisplatin—esophageal cancer	0.00057	0.0024	CcSEcCtD
Cladribine—Abdominal discomfort—Capecitabine—esophageal cancer	0.000569	0.0024	CcSEcCtD
Cladribine—Hepatic failure—Methotrexate—esophageal cancer	0.000569	0.0024	CcSEcCtD
Cladribine—Pancytopenia—Capecitabine—esophageal cancer	0.000564	0.00237	CcSEcCtD
Cladribine—Erythema—Cisplatin—esophageal cancer	0.000562	0.00236	CcSEcCtD
Cladribine—Malnutrition—Cisplatin—esophageal cancer	0.000562	0.00236	CcSEcCtD
Cladribine—Neutropenia—Capecitabine—esophageal cancer	0.000555	0.00234	CcSEcCtD
Cladribine—ABCG2—lymph node—esophageal cancer	0.000555	0.0041	CbGeAlD
Cladribine—Renal failure acute—Methotrexate—esophageal cancer	0.000554	0.00233	CcSEcCtD
Cladribine—Flatulence—Cisplatin—esophageal cancer	0.000553	0.00233	CcSEcCtD
Cladribine—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000552	0.00232	CcSEcCtD
Cladribine—Pneumonia—Capecitabine—esophageal cancer	0.000533	0.00224	CcSEcCtD
Cladribine—Infestation—Capecitabine—esophageal cancer	0.00053	0.00223	CcSEcCtD
Cladribine—Infestation NOS—Capecitabine—esophageal cancer	0.00053	0.00223	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000525	0.00221	CcSEcCtD
Cladribine—Lethargy—Methotrexate—esophageal cancer	0.000522	0.0022	CcSEcCtD
Cladribine—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000522	0.0022	CcSEcCtD
Cladribine—Ill-defined disorder—Cisplatin—esophageal cancer	0.000521	0.00219	CcSEcCtD
Cladribine—Renal failure—Capecitabine—esophageal cancer	0.000521	0.00219	CcSEcCtD
Cladribine—Anaemia—Cisplatin—esophageal cancer	0.000519	0.00218	CcSEcCtD
Cladribine—Urinary tract infection—Capecitabine—esophageal cancer	0.000515	0.00217	CcSEcCtD
Cladribine—Conjunctivitis—Capecitabine—esophageal cancer	0.000515	0.00217	CcSEcCtD
Cladribine—Malaise—Cisplatin—esophageal cancer	0.000506	0.00213	CcSEcCtD
Cladribine—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000501	0.00211	CcSEcCtD
Cladribine—Epistaxis—Capecitabine—esophageal cancer	0.0005	0.0021	CcSEcCtD
Cladribine—Ataxia—Methotrexate—esophageal cancer	0.000481	0.00203	CcSEcCtD
Cladribine—Myalgia—Cisplatin—esophageal cancer	0.000478	0.00201	CcSEcCtD
Cladribine—Haemoglobin—Capecitabine—esophageal cancer	0.000478	0.00201	CcSEcCtD
Cladribine—Anxiety—Cisplatin—esophageal cancer	0.000476	0.00201	CcSEcCtD
Cladribine—Haemorrhage—Capecitabine—esophageal cancer	0.000475	0.002	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000475	0.002	CcSEcCtD
Cladribine—Discomfort—Cisplatin—esophageal cancer	0.000472	0.00199	CcSEcCtD
Cladribine—Pharyngitis—Capecitabine—esophageal cancer	0.000472	0.00199	CcSEcCtD
Cladribine—Urinary tract disorder—Capecitabine—esophageal cancer	0.00047	0.00198	CcSEcCtD
Cladribine—Oedema peripheral—Capecitabine—esophageal cancer	0.000468	0.00197	CcSEcCtD
Cladribine—Connective tissue disorder—Capecitabine—esophageal cancer	0.000467	0.00197	CcSEcCtD
Cladribine—Urethral disorder—Capecitabine—esophageal cancer	0.000466	0.00196	CcSEcCtD
Cladribine—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000461	0.00194	CcSEcCtD
Cladribine—Oedema—Cisplatin—esophageal cancer	0.000458	0.00193	CcSEcCtD
Cladribine—Infection—Cisplatin—esophageal cancer	0.000455	0.00192	CcSEcCtD
Cladribine—Erythema multiforme—Capecitabine—esophageal cancer	0.00045	0.00189	CcSEcCtD
Cladribine—Nervous system disorder—Cisplatin—esophageal cancer	0.000449	0.00189	CcSEcCtD
Cladribine—Thrombocytopenia—Cisplatin—esophageal cancer	0.000449	0.00189	CcSEcCtD
Cladribine—Tachycardia—Cisplatin—esophageal cancer	0.000447	0.00188	CcSEcCtD
Cladribine—Skin disorder—Cisplatin—esophageal cancer	0.000445	0.00187	CcSEcCtD
Cladribine—Eye disorder—Capecitabine—esophageal cancer	0.000444	0.00187	CcSEcCtD
Cladribine—Hyperhidrosis—Cisplatin—esophageal cancer	0.000443	0.00186	CcSEcCtD
Cladribine—Cardiac disorder—Capecitabine—esophageal cancer	0.000441	0.00186	CcSEcCtD
Cladribine—Eosinophilia—Methotrexate—esophageal cancer	0.000438	0.00184	CcSEcCtD
Cladribine—Anorexia—Cisplatin—esophageal cancer	0.000437	0.00184	CcSEcCtD
Cladribine—Angiopathy—Capecitabine—esophageal cancer	0.000431	0.00182	CcSEcCtD
Cladribine—Immune system disorder—Capecitabine—esophageal cancer	0.000429	0.00181	CcSEcCtD
Cladribine—Mediastinal disorder—Capecitabine—esophageal cancer	0.000429	0.0018	CcSEcCtD
Cladribine—Hypotension—Cisplatin—esophageal cancer	0.000428	0.0018	CcSEcCtD
Cladribine—Chills—Capecitabine—esophageal cancer	0.000427	0.0018	CcSEcCtD
Cladribine—Arrhythmia—Capecitabine—esophageal cancer	0.000425	0.00179	CcSEcCtD
Cladribine—Abdominal discomfort—Methotrexate—esophageal cancer	0.000424	0.00178	CcSEcCtD
Cladribine—Alopecia—Capecitabine—esophageal cancer	0.00042	0.00177	CcSEcCtD
Cladribine—Pancytopenia—Methotrexate—esophageal cancer	0.00042	0.00177	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000418	0.00176	CcSEcCtD
Cladribine—Mental disorder—Capecitabine—esophageal cancer	0.000417	0.00175	CcSEcCtD
Cladribine—Erythema—Capecitabine—esophageal cancer	0.000414	0.00174	CcSEcCtD
Cladribine—Malnutrition—Capecitabine—esophageal cancer	0.000414	0.00174	CcSEcCtD
Cladribine—Neutropenia—Methotrexate—esophageal cancer	0.000414	0.00174	CcSEcCtD
Cladribine—Paraesthesia—Cisplatin—esophageal cancer	0.000412	0.00173	CcSEcCtD
Cladribine—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000411	0.00173	CcSEcCtD
Cladribine—Dyspnoea—Cisplatin—esophageal cancer	0.000409	0.00172	CcSEcCtD
Cladribine—Flatulence—Capecitabine—esophageal cancer	0.000408	0.00172	CcSEcCtD
Cladribine—Back pain—Capecitabine—esophageal cancer	0.0004	0.00169	CcSEcCtD
Cladribine—Decreased appetite—Cisplatin—esophageal cancer	0.000398	0.00168	CcSEcCtD
Cladribine—Pneumonia—Methotrexate—esophageal cancer	0.000397	0.00167	CcSEcCtD
Cladribine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000396	0.00167	CcSEcCtD
Cladribine—Infestation—Methotrexate—esophageal cancer	0.000394	0.00166	CcSEcCtD
Cladribine—Infestation NOS—Methotrexate—esophageal cancer	0.000394	0.00166	CcSEcCtD
Cladribine—Pain—Cisplatin—esophageal cancer	0.000392	0.00165	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000391	0.00165	CcSEcCtD
Cladribine—Renal failure—Methotrexate—esophageal cancer	0.000388	0.00163	CcSEcCtD
Cladribine—Ill-defined disorder—Capecitabine—esophageal cancer	0.000384	0.00162	CcSEcCtD
Cladribine—Conjunctivitis—Methotrexate—esophageal cancer	0.000383	0.00161	CcSEcCtD
Cladribine—Anaemia—Capecitabine—esophageal cancer	0.000383	0.00161	CcSEcCtD
Cladribine—Feeling abnormal—Cisplatin—esophageal cancer	0.000378	0.00159	CcSEcCtD
Cladribine—Malaise—Capecitabine—esophageal cancer	0.000373	0.00157	CcSEcCtD
Cladribine—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000373	0.00157	CcSEcCtD
Cladribine—Epistaxis—Methotrexate—esophageal cancer	0.000372	0.00157	CcSEcCtD
Cladribine—Body temperature increased—Cisplatin—esophageal cancer	0.000362	0.00152	CcSEcCtD
Cladribine—Cough—Capecitabine—esophageal cancer	0.000361	0.00152	CcSEcCtD
Cladribine—Haemoglobin—Methotrexate—esophageal cancer	0.000356	0.0015	CcSEcCtD
Cladribine—Haemorrhage—Methotrexate—esophageal cancer	0.000354	0.00149	CcSEcCtD
Cladribine—Chest pain—Capecitabine—esophageal cancer	0.000352	0.00148	CcSEcCtD
Cladribine—Myalgia—Capecitabine—esophageal cancer	0.000352	0.00148	CcSEcCtD
Cladribine—Arthralgia—Capecitabine—esophageal cancer	0.000352	0.00148	CcSEcCtD
Cladribine—Pharyngitis—Methotrexate—esophageal cancer	0.000351	0.00148	CcSEcCtD
Cladribine—Anxiety—Capecitabine—esophageal cancer	0.000351	0.00148	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00035	0.00147	CcSEcCtD
Cladribine—Urinary tract disorder—Methotrexate—esophageal cancer	0.00035	0.00147	CcSEcCtD
Cladribine—Discomfort—Capecitabine—esophageal cancer	0.000348	0.00147	CcSEcCtD
Cladribine—Urethral disorder—Methotrexate—esophageal cancer	0.000347	0.00146	CcSEcCtD
Cladribine—Confusional state—Capecitabine—esophageal cancer	0.000341	0.00143	CcSEcCtD
Cladribine—Oedema—Capecitabine—esophageal cancer	0.000338	0.00142	CcSEcCtD
Cladribine—Hypersensitivity—Cisplatin—esophageal cancer	0.000338	0.00142	CcSEcCtD
Cladribine—Infection—Capecitabine—esophageal cancer	0.000336	0.00141	CcSEcCtD
Cladribine—Erythema multiforme—Methotrexate—esophageal cancer	0.000335	0.00141	CcSEcCtD
Cladribine—Nervous system disorder—Capecitabine—esophageal cancer	0.000331	0.00139	CcSEcCtD
Cladribine—Eye disorder—Methotrexate—esophageal cancer	0.000331	0.00139	CcSEcCtD
Cladribine—Thrombocytopenia—Capecitabine—esophageal cancer	0.000331	0.00139	CcSEcCtD
Cladribine—Tachycardia—Capecitabine—esophageal cancer	0.00033	0.00139	CcSEcCtD
Cladribine—Asthenia—Cisplatin—esophageal cancer	0.000329	0.00138	CcSEcCtD
Cladribine—Cardiac disorder—Methotrexate—esophageal cancer	0.000329	0.00138	CcSEcCtD
Cladribine—Skin disorder—Capecitabine—esophageal cancer	0.000328	0.00138	CcSEcCtD
Cladribine—Hyperhidrosis—Capecitabine—esophageal cancer	0.000327	0.00137	CcSEcCtD
Cladribine—Anorexia—Capecitabine—esophageal cancer	0.000322	0.00136	CcSEcCtD
Cladribine—Angiopathy—Methotrexate—esophageal cancer	0.000321	0.00135	CcSEcCtD
Cladribine—Immune system disorder—Methotrexate—esophageal cancer	0.00032	0.00135	CcSEcCtD
Cladribine—Mediastinal disorder—Methotrexate—esophageal cancer	0.000319	0.00134	CcSEcCtD
Cladribine—Chills—Methotrexate—esophageal cancer	0.000318	0.00134	CcSEcCtD
Cladribine—Hypotension—Capecitabine—esophageal cancer	0.000316	0.00133	CcSEcCtD
Cladribine—Diarrhoea—Cisplatin—esophageal cancer	0.000314	0.00132	CcSEcCtD
Cladribine—Alopecia—Methotrexate—esophageal cancer	0.000313	0.00132	CcSEcCtD
Cladribine—Mental disorder—Methotrexate—esophageal cancer	0.00031	0.00131	CcSEcCtD
Cladribine—Malnutrition—Methotrexate—esophageal cancer	0.000308	0.0013	CcSEcCtD
Cladribine—Erythema—Methotrexate—esophageal cancer	0.000308	0.0013	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000308	0.0013	CcSEcCtD
Cladribine—Insomnia—Capecitabine—esophageal cancer	0.000306	0.00129	CcSEcCtD
Cladribine—Paraesthesia—Capecitabine—esophageal cancer	0.000303	0.00128	CcSEcCtD
Cladribine—Dyspnoea—Capecitabine—esophageal cancer	0.000301	0.00127	CcSEcCtD
Cladribine—Back pain—Methotrexate—esophageal cancer	0.000298	0.00125	CcSEcCtD
Cladribine—Decreased appetite—Capecitabine—esophageal cancer	0.000294	0.00124	CcSEcCtD
Cladribine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000292	0.00123	CcSEcCtD
Cladribine—Vomiting—Cisplatin—esophageal cancer	0.000291	0.00123	CcSEcCtD
Cladribine—Fatigue—Capecitabine—esophageal cancer	0.000291	0.00123	CcSEcCtD
Cladribine—Rash—Cisplatin—esophageal cancer	0.000289	0.00122	CcSEcCtD
Cladribine—Pain—Capecitabine—esophageal cancer	0.000289	0.00122	CcSEcCtD
Cladribine—Constipation—Capecitabine—esophageal cancer	0.000289	0.00122	CcSEcCtD
Cladribine—Dermatitis—Cisplatin—esophageal cancer	0.000289	0.00122	CcSEcCtD
Cladribine—Ill-defined disorder—Methotrexate—esophageal cancer	0.000286	0.0012	CcSEcCtD
Cladribine—Anaemia—Methotrexate—esophageal cancer	0.000285	0.0012	CcSEcCtD
Cladribine—Feeling abnormal—Capecitabine—esophageal cancer	0.000278	0.00117	CcSEcCtD
Cladribine—Malaise—Methotrexate—esophageal cancer	0.000278	0.00117	CcSEcCtD
Cladribine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000276	0.00116	CcSEcCtD
Cladribine—Nausea—Cisplatin—esophageal cancer	0.000272	0.00115	CcSEcCtD
Cladribine—Cough—Methotrexate—esophageal cancer	0.000269	0.00113	CcSEcCtD
Cladribine—Urticaria—Capecitabine—esophageal cancer	0.000268	0.00113	CcSEcCtD
Cladribine—Abdominal pain—Capecitabine—esophageal cancer	0.000267	0.00112	CcSEcCtD
Cladribine—Body temperature increased—Capecitabine—esophageal cancer	0.000267	0.00112	CcSEcCtD
Cladribine—Chest pain—Methotrexate—esophageal cancer	0.000262	0.0011	CcSEcCtD
Cladribine—Myalgia—Methotrexate—esophageal cancer	0.000262	0.0011	CcSEcCtD
Cladribine—Arthralgia—Methotrexate—esophageal cancer	0.000262	0.0011	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000261	0.0011	CcSEcCtD
Cladribine—Discomfort—Methotrexate—esophageal cancer	0.000259	0.00109	CcSEcCtD
Cladribine—Confusional state—Methotrexate—esophageal cancer	0.000254	0.00107	CcSEcCtD
Cladribine—Infection—Methotrexate—esophageal cancer	0.00025	0.00105	CcSEcCtD
Cladribine—Hypersensitivity—Capecitabine—esophageal cancer	0.000249	0.00105	CcSEcCtD
Cladribine—Nervous system disorder—Methotrexate—esophageal cancer	0.000247	0.00104	CcSEcCtD
Cladribine—Thrombocytopenia—Methotrexate—esophageal cancer	0.000246	0.00104	CcSEcCtD
Cladribine—Skin disorder—Methotrexate—esophageal cancer	0.000244	0.00103	CcSEcCtD
Cladribine—Hyperhidrosis—Methotrexate—esophageal cancer	0.000243	0.00102	CcSEcCtD
Cladribine—Asthenia—Capecitabine—esophageal cancer	0.000242	0.00102	CcSEcCtD
Cladribine—Anorexia—Methotrexate—esophageal cancer	0.00024	0.00101	CcSEcCtD
Cladribine—Pruritus—Capecitabine—esophageal cancer	0.000239	0.00101	CcSEcCtD
Cladribine—Hypotension—Methotrexate—esophageal cancer	0.000235	0.000989	CcSEcCtD
Cladribine—Diarrhoea—Capecitabine—esophageal cancer	0.000231	0.000973	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000229	0.000964	CcSEcCtD
Cladribine—Insomnia—Methotrexate—esophageal cancer	0.000227	0.000957	CcSEcCtD
Cladribine—Paraesthesia—Methotrexate—esophageal cancer	0.000226	0.00095	CcSEcCtD
Cladribine—Dyspnoea—Methotrexate—esophageal cancer	0.000224	0.000944	CcSEcCtD
Cladribine—Somnolence—Methotrexate—esophageal cancer	0.000224	0.000941	CcSEcCtD
Cladribine—Dizziness—Capecitabine—esophageal cancer	0.000223	0.00094	CcSEcCtD
Cladribine—Decreased appetite—Methotrexate—esophageal cancer	0.000219	0.00092	CcSEcCtD
Cladribine—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000217	0.000914	CcSEcCtD
Cladribine—Fatigue—Methotrexate—esophageal cancer	0.000217	0.000913	CcSEcCtD
Cladribine—Pain—Methotrexate—esophageal cancer	0.000215	0.000905	CcSEcCtD
Cladribine—Vomiting—Capecitabine—esophageal cancer	0.000215	0.000904	CcSEcCtD
Cladribine—Rash—Capecitabine—esophageal cancer	0.000213	0.000897	CcSEcCtD
Cladribine—Dermatitis—Capecitabine—esophageal cancer	0.000213	0.000896	CcSEcCtD
Cladribine—Headache—Capecitabine—esophageal cancer	0.000212	0.000891	CcSEcCtD
Cladribine—Feeling abnormal—Methotrexate—esophageal cancer	0.000207	0.000872	CcSEcCtD
Cladribine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000206	0.000866	CcSEcCtD
Cladribine—Nausea—Capecitabine—esophageal cancer	0.000201	0.000845	CcSEcCtD
Cladribine—Urticaria—Methotrexate—esophageal cancer	0.0002	0.000841	CcSEcCtD
Cladribine—Abdominal pain—Methotrexate—esophageal cancer	0.000199	0.000837	CcSEcCtD
Cladribine—Body temperature increased—Methotrexate—esophageal cancer	0.000199	0.000837	CcSEcCtD
Cladribine—Hypersensitivity—Methotrexate—esophageal cancer	0.000185	0.00078	CcSEcCtD
Cladribine—Asthenia—Methotrexate—esophageal cancer	0.00018	0.000759	CcSEcCtD
Cladribine—Pruritus—Methotrexate—esophageal cancer	0.000178	0.000749	CcSEcCtD
Cladribine—Diarrhoea—Methotrexate—esophageal cancer	0.000172	0.000724	CcSEcCtD
Cladribine—Dizziness—Methotrexate—esophageal cancer	0.000166	0.0007	CcSEcCtD
Cladribine—Vomiting—Methotrexate—esophageal cancer	0.00016	0.000673	CcSEcCtD
Cladribine—Rash—Methotrexate—esophageal cancer	0.000159	0.000667	CcSEcCtD
Cladribine—Dermatitis—Methotrexate—esophageal cancer	0.000158	0.000667	CcSEcCtD
Cladribine—Headache—Methotrexate—esophageal cancer	0.000158	0.000663	CcSEcCtD
Cladribine—Nausea—Methotrexate—esophageal cancer	0.000149	0.000629	CcSEcCtD
Cladribine—RRM1—Metabolism—ALDH2—esophageal cancer	9.68e-05	0.000362	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CHEK2—esophageal cancer	9.65e-05	0.000361	CbGpPWpGaD
Cladribine—POLA1—Mitotic G1-G1/S phases—MYC—esophageal cancer	9.58e-05	0.000358	CbGpPWpGaD
Cladribine—DCK—Metabolism—ALOX15—esophageal cancer	9.58e-05	0.000358	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—CCND1—esophageal cancer	9.54e-05	0.000357	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—AQP3—esophageal cancer	9.5e-05	0.000355	CbGpPWpGaD
Cladribine—RRM2—Metabolism—ALDOB—esophageal cancer	9.38e-05	0.000351	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—CDKN1A—esophageal cancer	9.23e-05	0.000345	CbGpPWpGaD
Cladribine—RRM1—Metabolism—GSTT1—esophageal cancer	9.21e-05	0.000344	CbGpPWpGaD
Cladribine—DCK—Metabolism—TPI1—esophageal cancer	9.14e-05	0.000342	CbGpPWpGaD
Cladribine—DCK—Metabolism—GSTO1—esophageal cancer	9.14e-05	0.000342	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	9.11e-05	0.000341	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	9.11e-05	0.000341	CbGpPWpGaD
Cladribine—RRM1—Metabolism—CYP2A6—esophageal cancer	9.1e-05	0.00034	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	9.05e-05	0.000338	CbGpPWpGaD
Cladribine—RRM2—Metabolism—GAPDH—esophageal cancer	9.03e-05	0.000338	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—EP300—esophageal cancer	8.95e-05	0.000335	CbGpPWpGaD
Cladribine—RRM2—Metabolism—CRABP1—esophageal cancer	8.94e-05	0.000335	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—EP300—esophageal cancer	8.78e-05	0.000328	CbGpPWpGaD
Cladribine—DCK—Metabolism—ALDOB—esophageal cancer	8.76e-05	0.000328	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	8.75e-05	0.000327	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PTGS1—esophageal cancer	8.63e-05	0.000323	CbGpPWpGaD
Cladribine—RRM1—Metabolism—ENO1—esophageal cancer	8.63e-05	0.000323	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—RB1—esophageal cancer	8.62e-05	0.000323	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—CCND1—esophageal cancer	8.53e-05	0.000319	CbGpPWpGaD
Cladribine—RRM2—Metabolism—GNG7—esophageal cancer	8.51e-05	0.000318	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PSME2—esophageal cancer	8.5e-05	0.000318	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PSME1—esophageal cancer	8.5e-05	0.000318	CbGpPWpGaD
Cladribine—DCK—Metabolism—GAPDH—esophageal cancer	8.43e-05	0.000315	CbGpPWpGaD
Cladribine—DCK—Metabolism—CRABP1—esophageal cancer	8.36e-05	0.000313	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	8.33e-05	0.000312	CbGpPWpGaD
Cladribine—NR5A1—Generic Transcription Pathway—MYC—esophageal cancer	8.28e-05	0.00031	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—RB1—esophageal cancer	8.28e-05	0.00031	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—CDKN1A—esophageal cancer	8.25e-05	0.000309	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—CREBBP—esophageal cancer	8.11e-05	0.000303	CbGpPWpGaD
Cladribine—RRM2—Metabolism—ALDH2—esophageal cancer	7.97e-05	0.000298	CbGpPWpGaD
Cladribine—DCK—Metabolism—GNG7—esophageal cancer	7.95e-05	0.000297	CbGpPWpGaD
Cladribine—POLA1—Mitotic M-M/G1 phases—RB1—esophageal cancer	7.89e-05	0.000295	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—EP300—esophageal cancer	7.85e-05	0.000294	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—RB1—esophageal cancer	7.71e-05	0.000288	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—MYC—esophageal cancer	7.65e-05	0.000286	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—EGFR—esophageal cancer	7.63e-05	0.000285	CbGpPWpGaD
Cladribine—RRM2—Metabolism—GSTT1—esophageal cancer	7.58e-05	0.000284	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—CDKN2A—esophageal cancer	7.58e-05	0.000284	CbGpPWpGaD
Cladribine—RRM2—Metabolism—CYP2A6—esophageal cancer	7.5e-05	0.00028	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—ABCC2—esophageal cancer	7.49e-05	0.00028	CbGpPWpGaD
Cladribine—DCK—Metabolism—ALDH2—esophageal cancer	7.45e-05	0.000279	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—NOTCH1—esophageal cancer	7.41e-05	0.000277	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—ABCC2—esophageal cancer	7.41e-05	0.000277	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—RB1—esophageal cancer	7.4e-05	0.000277	CbGpPWpGaD
Cladribine—RRM1—Metabolism—CYP1B1—esophageal cancer	7.34e-05	0.000274	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—CDKN2A—esophageal cancer	7.28e-05	0.000272	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—NOS3—esophageal cancer	7.26e-05	0.000272	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	7.26e-05	0.000271	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PTGS1—esophageal cancer	7.11e-05	0.000266	CbGpPWpGaD
Cladribine—RRM2—Metabolism—ENO1—esophageal cancer	7.11e-05	0.000266	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	7.1e-05	0.000266	CbGpPWpGaD
Cladribine—DCK—Metabolism—GSTT1—esophageal cancer	7.09e-05	0.000265	CbGpPWpGaD
Cladribine—PNP—Metabolism—CREBBP—esophageal cancer	7.03e-05	0.000263	CbGpPWpGaD
Cladribine—DCK—Metabolism—CYP2A6—esophageal cancer	7e-05	0.000262	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PSME2—esophageal cancer	7e-05	0.000262	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PSME1—esophageal cancer	7e-05	0.000262	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	6.91e-05	0.000258	CbGpPWpGaD
Cladribine—RRM1—Metabolism—CYP19A1—esophageal cancer	6.9e-05	0.000258	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—MYC—esophageal cancer	6.84e-05	0.000256	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—GNG7—esophageal cancer	6.79e-05	0.000254	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—CDKN2A—esophageal cancer	6.78e-05	0.000254	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—GNG7—esophageal cancer	6.72e-05	0.000251	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—CREBBP—esophageal cancer	6.72e-05	0.000251	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—SLC52A3—esophageal cancer	6.68e-05	0.00025	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—BLVRB—esophageal cancer	6.68e-05	0.00025	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PTGS2—esophageal cancer	6.64e-05	0.000248	CbGpPWpGaD
Cladribine—DCK—Metabolism—PTGS1—esophageal cancer	6.64e-05	0.000248	CbGpPWpGaD
Cladribine—DCK—Metabolism—ENO1—esophageal cancer	6.64e-05	0.000248	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—BLVRB—esophageal cancer	6.61e-05	0.000247	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—SLC52A3—esophageal cancer	6.61e-05	0.000247	CbGpPWpGaD
Cladribine—DCK—Metabolism—PSME2—esophageal cancer	6.54e-05	0.000245	CbGpPWpGaD
Cladribine—DCK—Metabolism—PSME1—esophageal cancer	6.54e-05	0.000245	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—CDKN2A—esophageal cancer	6.51e-05	0.000243	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—CCND1—esophageal cancer	6.4e-05	0.00024	CbGpPWpGaD
Cladribine—PNP—Metabolism—NOS3—esophageal cancer	6.29e-05	0.000235	CbGpPWpGaD
Cladribine—RRM1—Metabolism—HMOX1—esophageal cancer	6.29e-05	0.000235	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—GNG7—esophageal cancer	6.27e-05	0.000234	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—CDKN1A—esophageal cancer	6.2e-05	0.000232	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	6.16e-05	0.00023	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—SLC52A3—esophageal cancer	6.16e-05	0.00023	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—BLVRB—esophageal cancer	6.16e-05	0.00023	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—CCND1—esophageal cancer	6.15e-05	0.00023	CbGpPWpGaD
Cladribine—RRM2—Metabolism—CYP1B1—esophageal cancer	6.04e-05	0.000226	CbGpPWpGaD
Cladribine—RRM1—Metabolism—ABCB1—esophageal cancer	6.04e-05	0.000226	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	5.96e-05	0.000223	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—CDKN1A—esophageal cancer	5.95e-05	0.000222	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—RB1—esophageal cancer	5.9e-05	0.000221	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—EP300—esophageal cancer	5.9e-05	0.00022	CbGpPWpGaD
Cladribine—PNP—Metabolism—PTGS2—esophageal cancer	5.76e-05	0.000215	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—CCND1—esophageal cancer	5.73e-05	0.000214	CbGpPWpGaD
Cladribine—RRM2—Metabolism—CYP19A1—esophageal cancer	5.68e-05	0.000212	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—SLC10A2—esophageal cancer	5.68e-05	0.000212	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CA1—esophageal cancer	5.68e-05	0.000212	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—EP300—esophageal cancer	5.66e-05	0.000212	CbGpPWpGaD
Cladribine—DCK—Metabolism—CYP1B1—esophageal cancer	5.65e-05	0.000211	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—TP53—esophageal cancer	5.62e-05	0.00021	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—SLC10A2—esophageal cancer	5.62e-05	0.00021	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CA1—esophageal cancer	5.62e-05	0.00021	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—CDKN1A—esophageal cancer	5.54e-05	0.000207	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—EP300—esophageal cancer	5.52e-05	0.000207	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—CCND1—esophageal cancer	5.5e-05	0.000206	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—CDKN1A—esophageal cancer	5.32e-05	0.000199	CbGpPWpGaD
Cladribine—DCK—Metabolism—CYP19A1—esophageal cancer	5.31e-05	0.000199	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—RB1—esophageal cancer	5.27e-05	0.000197	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—EP300—esophageal cancer	5.27e-05	0.000197	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CA1—esophageal cancer	5.24e-05	0.000196	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—SLC10A2—esophageal cancer	5.24e-05	0.000196	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CA2—esophageal cancer	5.19e-05	0.000194	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CDKN2A—esophageal cancer	5.19e-05	0.000194	CbGpPWpGaD
Cladribine—RRM2—Metabolism—HMOX1—esophageal cancer	5.18e-05	0.000194	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CA2—esophageal cancer	5.14e-05	0.000192	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—MYC—esophageal cancer	5.14e-05	0.000192	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—EP300—esophageal cancer	5.06e-05	0.000189	CbGpPWpGaD
Cladribine—RRM2—Metabolism—ABCB1—esophageal cancer	4.98e-05	0.000186	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—MYC—esophageal cancer	4.93e-05	0.000184	CbGpPWpGaD
Cladribine—DCK—Metabolism—HMOX1—esophageal cancer	4.84e-05	0.000181	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PLCE1—esophageal cancer	4.83e-05	0.00018	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ADH7—esophageal cancer	4.83e-05	0.00018	CbGpPWpGaD
Cladribine—PNP—Metabolism—EP300—esophageal cancer	4.79e-05	0.000179	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CA2—esophageal cancer	4.79e-05	0.000179	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ADH7—esophageal cancer	4.78e-05	0.000179	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PLCE1—esophageal cancer	4.78e-05	0.000179	CbGpPWpGaD
Cladribine—DCK—Metabolism—ABCB1—esophageal cancer	4.65e-05	0.000174	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CDKN2A—esophageal cancer	4.64e-05	0.000173	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—MYC—esophageal cancer	4.59e-05	0.000172	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ADH7—esophageal cancer	4.45e-05	0.000166	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PLCE1—esophageal cancer	4.45e-05	0.000166	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—MYC—esophageal cancer	4.41e-05	0.000165	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CCND1—esophageal cancer	4.38e-05	0.000164	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CDKN1A—esophageal cancer	4.24e-05	0.000158	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ADH1B—esophageal cancer	4.23e-05	0.000158	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ADH1B—esophageal cancer	4.19e-05	0.000157	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	4.14e-05	0.000155	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	4.1e-05	0.000153	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PIK3CA—esophageal cancer	4.09e-05	0.000153	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—TYMP—esophageal cancer	4.04e-05	0.000151	CbGpPWpGaD
Cladribine—RRM1—Metabolism—CREBBP—esophageal cancer	4.04e-05	0.000151	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—EP300—esophageal cancer	4.03e-05	0.000151	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—TYMP—esophageal cancer	4e-05	0.00015	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—MYC—esophageal cancer	3.99e-05	0.000149	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	3.97e-05	0.000149	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CYP26A1—esophageal cancer	3.93e-05	0.000147	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	3.93e-05	0.000147	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CCND1—esophageal cancer	3.92e-05	0.000146	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ADH1B—esophageal cancer	3.9e-05	0.000146	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CYP26A1—esophageal cancer	3.89e-05	0.000146	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ALOX15—esophageal cancer	3.83e-05	0.000143	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	3.82e-05	0.000143	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ALOX15—esophageal cancer	3.79e-05	0.000142	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CDKN1A—esophageal cancer	3.79e-05	0.000142	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—TP53—esophageal cancer	3.77e-05	0.000141	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—TYMP—esophageal cancer	3.73e-05	0.00014	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—ABCB1—esophageal cancer	3.66e-05	0.000137	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—TPI1—esophageal cancer	3.66e-05	0.000137	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTO1—esophageal cancer	3.66e-05	0.000137	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CYP26A1—esophageal cancer	3.63e-05	0.000136	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TP53—esophageal cancer	3.62e-05	0.000135	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—TPI1—esophageal cancer	3.62e-05	0.000135	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTO1—esophageal cancer	3.62e-05	0.000135	CbGpPWpGaD
Cladribine—RRM1—Metabolism—NOS3—esophageal cancer	3.62e-05	0.000135	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—EP300—esophageal cancer	3.61e-05	0.000135	CbGpPWpGaD
Cladribine—PNP—Metabolism—PIK3CA—esophageal cancer	3.54e-05	0.000132	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ALOX15—esophageal cancer	3.54e-05	0.000132	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—MYC—esophageal cancer	3.51e-05	0.000131	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ALDOB—esophageal cancer	3.51e-05	0.000131	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ALDOB—esophageal cancer	3.47e-05	0.00013	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GAPDH—esophageal cancer	3.38e-05	0.000126	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTO1—esophageal cancer	3.37e-05	0.000126	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—TPI1—esophageal cancer	3.37e-05	0.000126	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CRABP1—esophageal cancer	3.35e-05	0.000125	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GAPDH—esophageal cancer	3.34e-05	0.000125	CbGpPWpGaD
Cladribine—RRM2—Metabolism—CREBBP—esophageal cancer	3.33e-05	0.000124	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CRABP1—esophageal cancer	3.31e-05	0.000124	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PTGS2—esophageal cancer	3.31e-05	0.000124	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ALDOB—esophageal cancer	3.23e-05	0.000121	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GNG7—esophageal cancer	3.18e-05	0.000119	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GNG7—esophageal cancer	3.15e-05	0.000118	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MYC—esophageal cancer	3.14e-05	0.000118	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GAPDH—esophageal cancer	3.11e-05	0.000116	CbGpPWpGaD
Cladribine—DCK—Metabolism—CREBBP—esophageal cancer	3.11e-05	0.000116	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CRABP1—esophageal cancer	3.09e-05	0.000115	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ALDH2—esophageal cancer	2.98e-05	0.000112	CbGpPWpGaD
Cladribine—RRM2—Metabolism—NOS3—esophageal cancer	2.98e-05	0.000111	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ALDH2—esophageal cancer	2.95e-05	0.00011	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GNG7—esophageal cancer	2.93e-05	0.00011	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTT1—esophageal cancer	2.84e-05	0.000106	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTT1—esophageal cancer	2.81e-05	0.000105	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CYP2A6—esophageal cancer	2.8e-05	0.000105	CbGpPWpGaD
Cladribine—DCK—Metabolism—NOS3—esophageal cancer	2.78e-05	0.000104	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CYP2A6—esophageal cancer	2.77e-05	0.000104	CbGpPWpGaD
Cladribine—RRM1—Metabolism—EP300—esophageal cancer	2.75e-05	0.000103	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ALDH2—esophageal cancer	2.75e-05	0.000103	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PTGS2—esophageal cancer	2.72e-05	0.000102	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ENO1—esophageal cancer	2.66e-05	9.94e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PTGS1—esophageal cancer	2.66e-05	9.94e-05	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.66e-05	9.93e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ENO1—esophageal cancer	2.63e-05	9.84e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PTGS1—esophageal cancer	2.63e-05	9.84e-05	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.63e-05	9.83e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PSME2—esophageal cancer	2.62e-05	9.79e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PSME1—esophageal cancer	2.62e-05	9.79e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTT1—esophageal cancer	2.62e-05	9.78e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PSME1—esophageal cancer	2.59e-05	9.69e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PSME2—esophageal cancer	2.59e-05	9.69e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CYP2A6—esophageal cancer	2.59e-05	9.67e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TP53—esophageal cancer	2.58e-05	9.65e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PTGS2—esophageal cancer	2.54e-05	9.52e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PTGS1—esophageal cancer	2.45e-05	9.17e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ENO1—esophageal cancer	2.45e-05	9.17e-05	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.45e-05	9.16e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PSME1—esophageal cancer	2.42e-05	9.03e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PSME2—esophageal cancer	2.42e-05	9.03e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—EP300—esophageal cancer	2.26e-05	8.47e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CYP1B1—esophageal cancer	2.26e-05	8.45e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CYP1B1—esophageal cancer	2.24e-05	8.36e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CYP19A1—esophageal cancer	2.12e-05	7.94e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—EP300—esophageal cancer	2.12e-05	7.91e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CYP19A1—esophageal cancer	2.1e-05	7.86e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CYP1B1—esophageal cancer	2.08e-05	7.79e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PIK3CA—esophageal cancer	2.03e-05	7.61e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CYP19A1—esophageal cancer	1.96e-05	7.33e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—HMOX1—esophageal cancer	1.94e-05	7.25e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—HMOX1—esophageal cancer	1.92e-05	7.17e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ABCB1—esophageal cancer	1.86e-05	6.96e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ABCB1—esophageal cancer	1.84e-05	6.89e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—HMOX1—esophageal cancer	1.79e-05	6.69e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ABCB1—esophageal cancer	1.72e-05	6.42e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PIK3CA—esophageal cancer	1.68e-05	6.27e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PIK3CA—esophageal cancer	1.57e-05	5.85e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CREBBP—esophageal cancer	1.24e-05	4.65e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CREBBP—esophageal cancer	1.23e-05	4.6e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CREBBP—esophageal cancer	1.15e-05	4.29e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—NOS3—esophageal cancer	1.11e-05	4.16e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—NOS3—esophageal cancer	1.1e-05	4.12e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—NOS3—esophageal cancer	1.03e-05	3.84e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PTGS2—esophageal cancer	1.02e-05	3.81e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PTGS2—esophageal cancer	1.01e-05	3.77e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PTGS2—esophageal cancer	9.39e-06	3.51e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—EP300—esophageal cancer	8.47e-06	3.17e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—EP300—esophageal cancer	8.38e-06	3.13e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—EP300—esophageal cancer	7.81e-06	2.92e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PIK3CA—esophageal cancer	6.27e-06	2.34e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PIK3CA—esophageal cancer	6.2e-06	2.32e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PIK3CA—esophageal cancer	5.78e-06	2.16e-05	CbGpPWpGaD
